Comparison of Prior Distributions for the Heterogeneity Parameter in a Rare Events Meta-Analysis of a Few Studies.

Pharm Stat

Institute of Neurosurgery and Chinese Evidence-Based Medicine Center and Cochrane China Center and MAGIC China Center, West China Hospital, Sichuan University, Chengdu, China.

Published: October 2024

Bayesian meta-analysis is a promising approach for rare events meta-analysis. However, the inference of the overall effect in rare events meta-analysis is sensitive to the choice of prior distribution for the heterogeneity parameter. Therefore, it is crucial to assign a convincing prior specification and ensure that it is both plausible and transparent. Various priors for the heterogeneity parameter have been proposed; however, the comparative performance of alternative prior specifications in rare events meta-analysis is poorly understood. Based on a binomial-normal hierarchical model, we conducted a comprehensive simulation study to compare seven heterogeneity prior specifications for binary outcomes, using the odds ratio as the metric. We compared their performance in terms of coverage, median percentage bias, width of the 95% credible interval, and root mean square error (RMSE). We illustrate the results with two recently published rare events meta-analyses of a few studies. The results show that the half-normal prior (with a scale of 0.5), the prior proposed by Turner et al. for the general healthcare setting (without restriction to a specific type of outcome) and for the adverse event setting perform well when the degree of heterogeneity is not relatively high, yielding smaller bias and shorter interval widths with similar coverage and RMSE in most cases compared to other prior specifications. None of the priors performed better when the heterogeneity between-studies were significantly extreme.

Download full-text PDF

Source
http://dx.doi.org/10.1002/pst.2448DOI Listing

Publication Analysis

Top Keywords

rare events
20
events meta-analysis
16
heterogeneity parameter
12
prior specifications
12
prior
7
heterogeneity
6
rare
5
events
5
meta-analysis
5
comparison prior
4

Similar Publications

Introduction: Eculizumab is a C5 complement inhibitor approved by the FDA for the targeted treatment of four rare diseases, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and aquaporin-4 immunoglobulin G-positive optic neuromyelitis optica spectrum disorders (AQP4-IgG+NMOSD). The current study was conducted to assess real-world adverse events (AEs) associated with eculizumab through data mining of the FDA Adverse Event Reporting System (FAERS).

Methods: Disproportionality analyses, including Reporting Ratio Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-Item Gamma Poisson Shrinker (MGPS) algorithms were used to quantify the signals of eculizumab-associated AEs.

View Article and Find Full Text PDF

Background: Osteoarthritis (OA) is a prevalent joint disorder requiring innovative treatment approaches.

Aim: To evaluate the use of nanofat, a specialized form of adipose tissue-derived cells, in the treatment of OA, by examining its efficacy, safety profile, mechanisms of action, comparative effectiveness, and long-term outcomes.

Methods: A comprehensive review of preclinical studies, clinical trials, and investigations was conducted.

View Article and Find Full Text PDF

Introduction: Pembrolizumab is an immune checkpoint inhibitor widely administered for the treatment of various malignancies. Despite its effectiveness, its distinctive mechanism of action may lead to immune-related adverse events, most frequently affecting cutaneous tissues. Hair-related adverse events, although uncommon, include conditions such as alopecia areata and alterations in hair texture or type.

View Article and Find Full Text PDF

Cold climate-driven convergent evolution among angiosperms.

Plant Commun

January 2025

State Key Laboratory of Subtropical Silviculture, College of Forestry and Biotechnology, Zhejiang A&F University; Hangzhou 311300, China; Zhejiang International Science and Technology Cooperation Base for Plant Germplasm Resources Conservation and Utilization, Zhejiang A&F University; Hangzhou 311300, China; Provincial Key Laboratory for Non-wood Forest and Quality Control and Utilization of Its Products, Zhejiang A&F University, Hangzhou 311300, China. Electronic address:

Convergent and parallel evolution occur more frequently than previously thought. Here, we focus on the evolutionary adaptations of angiosperms to sub-zero temperatures. We begin by introducing the research history of convergent and parallel evolution, defining all independent similarities as convergent evolution.

View Article and Find Full Text PDF

Surgical treatment of anomalous aortic origin of the coronary artery in paediatric patients: a Chinese single-center experience.

BMC Surg

January 2025

Department of Cardiothoracic Surgery, Heart Center, School of Medicine, Shanghai Children's Medical Center, Shanghai Jiaotong University, Shanghai, China.

Purpose: An anomalous aortic origin of the coronary artery (AAOCA) is a rare congenital heart disease. Some high-risk anatomical structures are at risk of inducing cardiogenic shock or even sudden death. This article summarizes our surgical experience with AAOCA in paediatric patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!